Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents

NCT00665847 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT00665847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00665847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
August 31, 2011
Enrollment
103 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1